Iovance Biotherapeutics (IOVA) Change in Acquisitions & Divestments (2015 - 2026)

Iovance Biotherapeutics (IOVA) has reported Change in Acquisitions & Divestments for 12 consecutive years, with $74.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 38.33% year-over-year to $74.0 million; the TTM figure through Mar 2026 stood at $354.0 million (down 23.21% YoY), while the FY2025 annual figure was $400.0 million, down 6.54% from the prior year.
• Change in Acquisitions & Divestments climbed to $74.0 million in Q1 2026 per IOVA's latest filing, from $70.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $164.4 million in Q1 2023 and bottomed at $21.0 million in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $100.6 million across 5 years, with a median of $110.0 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments slumped 84.98% — and 2024, when it surged 425.06%.
• Iovance Biotherapeutics' Change in Acquisitions & Divestments stood at $99.1 million in 2022, then sank by 61.66% to $38.0 million in 2023, then surged by 205.26% to $116.0 million in 2024, then slumped by 39.66% to $70.0 million in 2025, then increased by 5.71% to $74.0 million in 2026.
• Business Quant data shows IOVA's Change in Acquisitions & Divestments at $74.0 million in Q1 2026, $70.0 million in Q4 2025, and $120.0 million in Q3 2025.